Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tonix Pharmaceuticals Holding (TNXP) Return on Sales (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Return on Sales data on record, last reported at 9.68% in Q3 2025.

  • For Q3 2025, Return on Sales fell 416.0% year-over-year to 9.68%; the TTM value through Sep 2025 reached 9.58%, up 926.0%, while the annual FY2024 figure was 13.54%, 1117.0% down from the prior year.
  • Return on Sales reached 9.68% in Q3 2025 per TNXP's latest filing, up from 14.16% in the prior quarter.
  • Across five years, Return on Sales topped out at 5.51% in Q3 2024 and bottomed at 35.02% in Q2 2024.
  • Average Return on Sales over 3 years is 11.91%, with a median of 8.65% recorded in 2024.
  • Peak YoY movement for Return on Sales: crashed -2683bps in 2024, then surged 2085bps in 2025.
  • A 3-year view of Return on Sales shows it stood at 15.57% in 2023, then surged by 44bps to 8.71% in 2024, then dropped by -11bps to 9.68% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 9.68% in Q3 2025, 14.16% in Q2 2025, and 6.61% in Q1 2025.